- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00319488
Childhood Asthma Research and Education (CARE) Network Trial - Acute Intervention Management Strategies (AIMS) (AIMS)
July 28, 2016 updated by: National Heart, Lung, and Blood Institute (NHLBI)
This study will determine the effectiveness of initiating a high-dose inhaled corticosteroid (ICS) or a leukotriene receptor antagonist (LTRA) in addition to an inhaled beta2-agonist (albuterol) at the onset of respiratory tract illness (RTI)-associated symptoms in increasing episode-free days among young children with recurrent severe wheezing.
Study Overview
Status
Completed
Conditions
Detailed Description
Acute Intervention Management Strategies (AIMS) is a randomized, double-blind, double-dummy, placebo-controlled parallel comparison study that will compare the effectiveness of three treatments, when given at the onset of RTI-associated symptoms, in increasing the proportion of symptom-free days over the entire treatment period of the 5- to 9-month study.
There will be a 2-week period to qualify and characterize participants, who at that time will have no lower respiratory tract symptoms other than mild cough.
A total of 244 participants will be randomized to one of three treatment groups and followed for the remainder of the fall-winter-early spring season.
Participants will receive one of the following treatment regimens for 7 days, at the first sign of RTI-associated symptoms: 1) active ICS plus placebo LTRA plus albuterol inhalation treatments four times daily; 2) active LTRA plus placebo ICS plus albuterol inhalation treatment four times daily; or 3) placebo ICS plus placebo LTRA plus albuterol inhalation treatments four times daily.
Study Type
Interventional
Enrollment (Actual)
238
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Arizona
-
Tucson, Arizona, United States, 85724
- University of Arizona, College of Medicine
-
-
California
-
LaJolla, California, United States, 92093
- UCSD School of Medicine
-
-
Colorado
-
Denver, Colorado, United States, 80206
- National Jewish Medical and Research Center
-
-
Missouri
-
St. Louis, Missouri, United States, 63110
- Washington University School of Medicine Patient Oriented Research Unit
-
-
Pennsylvania
-
Hershey, Pennsylvania, United States, 17033
- Dept. of Health Evaluation Sciences, Penn State College of Medicine
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53792
- University of Wisconsin - Madison
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
1 year to 4 years (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Recurrent episodes (at least two) of wheezing in the context of a RTI, at least one of which must be documented by a health care provider (parental report) over the 12 months prior to study entry, and of which one episode must have occurred within 6 months prior to study entry
Either two episodes of '1,' OR two episodes of '2,' OR one episode of '1' AND one episode of '2,' defined by the following:
- Urgent care visit for acute wheezing (emergency department, urgent care center, or unscheduled primary care physician office visit), which required treatment with a bronchodilator, within 12 months prior to study entry
- Episode of wheezing within 12 months prior to study entry, which required treatment with oral corticosteroids not associated with a visit to a health care provider, urgent care center, emergency department, or hospital
- Immunizations are up to date, including varicella (unless the patient has already had clinical varicella)
- Willingness to provide informed consent by patient's parent or guardian
Exclusion Criteria:
- Use of more than six courses of systemic corticosteroids during the 12 months prior to study entry
- More than two hospitalizations for wheezing illnesses within 12 months prior to study entry
- Use of long-term controller medications for asthma (including inhaled corticosteroids, leukotriene modifiers, cromolyn/nedocromil, or theophylline) for 4 or more months (cumulative use) within 1 year prior to study entry
- Any use of long-term controller medications for asthma (including corticosteroids [inhaled or oral], leukotriene modifiers, cromolyn/nedocromil, or theophylline) within the 2 weeks prior to the enrollment visit
- Current treatment with antibiotics for diagnosed sinus disease
- Contraindication of use of systemic corticosteroids
- Prematurity (defined as birth before 36 weeks gestational age)
- Presence of lung disease other than asthma (e.g., cystic fibrosis and BPD)
- Presence of other significant medical illnesses (e.g., cardiac, liver, gastrointestinal, or endocrine disease) that would place the patient at increased risk
- Gastroesophageal reflux under medical therapy
- Immunodeficiency disorders
- History of respiratory failure requiring mechanical ventilation
- History of hypoxic seizure
- Inability to cooperate with nebulization therapy
- Inability to ingest the study drugs
- History of significant adverse reaction to any study medication ingredient
- Current participation, or participation in the month prior to study entry, in another investigational drug study
- Evidence that the family may be unreliable, nonadherent, or likely to move from the clinical center area before study completion
- Persistent symptomatic asthma, as defined as experiencing symptoms (i.e., nocturnal cough, daytime cough, wheezing, difficulty breathing, or symptoms interfering with activities) and/or requiring albuterol use on average 4 or more days per week in the 2-week observation period prior to the randomization visit
- The following scores, based on a 5-point scale with 5 representing very severe symptoms (measured at randomization visit): score equal to or greater than one for albuterol use, wheezing, difficulty breathing, nighttime cough, and asthma symptoms interfering with activities; score greater than 2 for daytime cough on an average of 4 or more days/week during the 2-week observation period
- Failure to complete diary cards at expected levels (at least 80% of days) during the observation period
- Use of long-term controller medications for asthma (e.g., corticosteroids [inhaled or oral], leukotriene modifiers, cromolyn/nedocromil, or theophylline) during the 2-week observation period
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: 1
Active ICS plus placebo LTRA plus albuterol inhalation treatments four times daily
|
Participants will receive inhaled corticosteroid for 7 days, at the first sign of RTI-associated symptoms.
All participants will receive inhaled albuterol treatments four times a day.
|
Active Comparator: 2
Active LTRA plus placebo ICS plus albuterol inhalation treatment four times daily
|
All participants will receive inhaled albuterol treatments four times a day.
Participants will receive leukotriene receptor antagonist for 7 days, at the first sign of RTI-associated symptoms.
|
Placebo Comparator: 3
Placebo ICS plus placebo LTRA plus albuterol inhalation treatments four times daily
|
All participants will receive inhaled albuterol treatments four times a day.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Proportion of episode-free days as determined by diary cards
Time Frame: Measured over 12-month follow-up period
|
Measured over 12-month follow-up period
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Time to initiation of first course of oral corticosteroids
Time Frame: Measured at Weeks 2, 4, 10, 12, 18, 20, 26, 28, 34, 36, 42, 44, 50, and 52 after randomization
|
Measured at Weeks 2, 4, 10, 12, 18, 20, 26, 28, 34, 36, 42, 44, 50, and 52 after randomization
|
Total number of courses of oral corticosteroids
Time Frame: Measured at Weeks 2, 4, 10, 12, 18, 20, 26, 28, 34, 36, 42, 44, 50, and 52 after randomization
|
Measured at Weeks 2, 4, 10, 12, 18, 20, 26, 28, 34, 36, 42, 44, 50, and 52 after randomization
|
Duration and severity of lower respiratory tract symptoms
Time Frame: Measured at Weeks 2, 4, 10, 12, 18, 20, 26, 28, 34, 36, 42, 44, 50, and 52 after randomization
|
Measured at Weeks 2, 4, 10, 12, 18, 20, 26, 28, 34, 36, 42, 44, 50, and 52 after randomization
|
Number of wheezing episodes
Time Frame: Measured at Weeks 2, 4, 10, 12, 18, 20, 26, 28, 34, 36, 42, 44, 50, and 52 after randomization
|
Measured at Weeks 2, 4, 10, 12, 18, 20, 26, 28, 34, 36, 42, 44, 50, and 52 after randomization
|
Time to treatment failure
Time Frame: Measured at Weeks 2, 4, 10, 12, 18, 20, 26, 28, 34, 36, 42, 44, 50, and 52 after randomization
|
Measured at Weeks 2, 4, 10, 12, 18, 20, 26, 28, 34, 36, 42, 44, 50, and 52 after randomization
|
Measures of patient and family morbidity
Time Frame: Measured at Weeks 2, 4, 10, 12, 18, 20, 26, 28, 34, 36, 42, 44, 50, and 52 after randomization
|
Measured at Weeks 2, 4, 10, 12, 18, 20, 26, 28, 34, 36, 42, 44, 50, and 52 after randomization
|
Number of unscheduled visits for acute wheezing episodes
Time Frame: Measured at Weeks 2, 4, 10, 12, 18, 20, 26, 28, 34, 36, 42, 44, 50, and 52 after randomization
|
Measured at Weeks 2, 4, 10, 12, 18, 20, 26, 28, 34, 36, 42, 44, 50, and 52 after randomization
|
Linear growth
Time Frame: Measured at Weeks 2, 4, 10, 12, 18, 20, 26, 28, 34, 36, 42, 44, 50, and 52 after randomization
|
Measured at Weeks 2, 4, 10, 12, 18, 20, 26, 28, 34, 36, 42, 44, 50, and 52 after randomization
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Vernon M. Chinchilli, PhD, Pennsylvania State University, College of Medicine
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2004
Primary Completion (Actual)
November 1, 2006
Study Completion (Actual)
November 1, 2006
Study Registration Dates
First Submitted
April 27, 2006
First Submitted That Met QC Criteria
April 27, 2006
First Posted (Estimate)
April 27, 2006
Study Record Updates
Last Update Posted (Estimate)
July 29, 2016
Last Update Submitted That Met QC Criteria
July 28, 2016
Last Verified
April 1, 2012
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Immune System Diseases
- Hypersensitivity, Immediate
- Bronchial Diseases
- Lung Diseases, Obstructive
- Respiratory Hypersensitivity
- Hypersensitivity
- Lung Diseases
- Asthma
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Anti-Inflammatory Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Adrenergic Agonists
- Bronchodilator Agents
- Anti-Asthmatic Agents
- Respiratory System Agents
- Hormone Antagonists
- Cytochrome P-450 CYP1A2 Inducers
- Cytochrome P-450 Enzyme Inducers
- Reproductive Control Agents
- Adrenergic beta-2 Receptor Agonists
- Adrenergic beta-Agonists
- Tocolytic Agents
- Budesonide
- Montelukast
- Albuterol
- Leukotriene Antagonists
Other Study ID Numbers
- 386
- 5U10HL064288 (U.S. NIH Grant/Contract)
- 5U10HL064305 (U.S. NIH Grant/Contract)
- 5U10HL064295 (U.S. NIH Grant/Contract)
- 5U10HL064287 (U.S. NIH Grant/Contract)
- 5U10HL064307 (U.S. NIH Grant/Contract)
- 5U10HL064313-07 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lung Diseases
-
Guangzhou Institute of Respiratory DiseaseUnknownInterstitial Lung Disease | Transbronchial Lung Cryobiopsy | Surgical Lung Biopsy
-
Aveiro UniversityFundação para a Ciência e a TecnologiaNot yet recruitingInterstitial Lung DiseasesPortugal
-
RWTH Aachen UniversityCompletedObstructive Lung DiseasesGermany
-
Bastiaan DriehuysNational Heart, Lung, and Blood Institute (NHLBI); University of Iowa; Children... and other collaboratorsRecruitingInterstitial Lung DiseasesUnited States
-
Shanghai East HospitalRegend TherapeuticsCompletedInterstitial Lung DiseasesChina
-
China-Japan Friendship HospitalXiangya Hospital of Central South University; Peking Union Medical College... and other collaboratorsUnknown
-
Academisch Medisch Centrum - Universiteit van Amsterdam...CompletedInterstitial Lung DiseasesNetherlands
-
Centre Hospitalier Universitaire de Saint EtienneCompleted
-
Aveiro UniversityFundação para a Ciência e a Tecnologia; Centro Hospitalar do Baixo VougaRecruitingInterstitial Lung Diseases (ILD)Portugal
-
China-Japan Friendship HospitalNot yet recruitingTransbronchial Lung Cryobiopsy
Clinical Trials on Inhaled Corticosteroid (Budesonide)
-
Ajou University School of MedicineAstraZenecaRecruitingAsthma | Osteoporosis Risk | Osteoporotic Fractures | Osteoporosis, OsteopeniaKorea, Republic of
-
Boehringer IngelheimCompletedPulmonary Disease, Chronic ObstructiveSpain
-
NovartisCompleted
-
Rafael StelmachFundação de Amparo à Pesquisa do Estado de São PauloCompleted
-
National Heart, Lung, and Blood Institute (NHLBI)Childhood Asthma Research and Education NetworkCompletedLung Diseases | Asthma
-
Pearl Therapeutics, Inc.Completed
-
Sun Yat-sen UniversityJIANGSU JIBEIER PHARMACEUTICAL CO.,LTDNot yet recruitingNasopharyngeal Carcinoma | Chemotherapy | Myelosuppression | LeucogenChina
-
University of NottinghamCompleted
-
Brigham and Women's HospitalPatient-Centered Outcomes Research Institute; American Academy of Family PhysiciansCompletedAsthmaUnited States, Puerto Rico
-
University of NottinghamKing's College LondonCompleted